Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01829711 · FLOW

Participant flow

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia · Source last updated 2020-04-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.
    id
    FG000
    title
    Moxetumomab Pasudotox 40 µg/kg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Lost to Follow-up
    2. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        17
      type
      Started new therapies
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Adverse Event
    6. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Due to progression of disease
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Due to lack of response
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        80
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        43
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
The study was conducted across 14 countries (the USA, France, Italy, Germany, Belgium, Canada, Czech Republic, Ireland, Israel, Norway, Poland, Serbia, Spain, and United Kingdom).
Complete source fields
groups
  1. description
    Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.
    id
    FG000
    title
    Moxetumomab Pasudotox 40 µg/kg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Lost to Follow-up
    2. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        17
      type
      Started new therapies
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Adverse Event
    6. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Due to progression of disease
    7. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Due to lack of response
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        80
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        43
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
The study was conducted across 14 countries (the USA, France, Italy, Germany, Belgium, Canada, Czech Republic, Ireland, Israel, Norway, Poland, Serbia, Spain, and United Kingdom).

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice